Literature DB >> 11229878

Apolipoprotein(a): structure and biology.

A M Scanu1, K Nakajima, C Edelstein.   

Abstract

Apolipoprotein(a), apo(a), the distinctive glycoprotein constituent of lipoprotein(a), Lp(a), is synthesized in the liver, links covalently to apoB100-lipoprotein, and travels so linked in the plasma to tissue sites where removal mechanisms are yet undetermined. Depending on the redox status of the surrounding milieu, apo(a) may re-acquire its unbound state shown to have structural and functional properties different from those of the bound form. Apo(a) is potentially athero-thrombogenic, a property which may be influenced by its size, sequence polymorphism, type of lipoprotein it is linked to and the inflammatory state of the vessel wall. This set of variables must be taken into account when assessing the cardiovascular pathogenicity of free and bound apo(a).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11229878     DOI: 10.2741/scanu

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  9 in total

Review 1.  Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism.

Authors:  R A Hegele
Journal:  Am J Hum Genet       Date:  2001-10-26       Impact factor: 11.025

2.  Modification of lipoprotein(a) by natural dicarbonyls induced their following free radical peroxidation.

Authors:  V Z Lankin; O I Afanasieva; G G Konovalova; E A Utkina; O A Dmitrieva; A K Tikhaze; E M Kumskova; S N Pokrovsky
Journal:  Dokl Biochem Biophys       Date:  2012-01-06       Impact factor: 0.788

3.  Naturally occurring human plasminogen, like genetically related apolipoprotein(a), contains oxidized phosphatidylcholine adducts.

Authors:  Celina Edelstein; Ditta Pfaffinger; Ming Yang; John S Hill; Angelo M Scanu
Journal:  Biochim Biophys Acta       Date:  2010-03-24

Review 4.  Lipoprotein(a) and the atherothrombotic process: mechanistic insights and clinical implications.

Authors:  Angelo M Scanu
Journal:  Curr Atheroscler Rep       Date:  2003-03       Impact factor: 5.113

5.  Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels.

Authors:  Angelo M Scanu; Janet Hinman
Journal:  Lipids       Date:  2002-05       Impact factor: 1.880

6.  Proteome-based identification of apolipoprotein A-IV as an early diagnostic biomarker in liver fibrosis.

Authors:  Pei-Wen Wang; Yu-Ching Hung; Tung-Ho Wu; Mu-Hong Chen; Chau-Ting Yeh; Tai-Long Pan
Journal:  Oncotarget       Date:  2017-10-06

7.  Lipoprotein(a) is not related to markers of insulin resistance in pregnancy.

Authors:  Jelena Todoric; Ammon Handisurya; Karoline Leitner; Juergen Harreiter; Gregor Hoermann; Alexandra Kautzky-Willer
Journal:  Cardiovasc Diabetol       Date:  2013-10-01       Impact factor: 9.951

Review 8.  Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological role.

Authors:  Alexandros D Tselepis
Journal:  J Biomed Res       Date:  2018-01-26

Review 9.  Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies.

Authors:  Ahmed Handhle; Adie Viljoen; Anthony S Wierzbicki
Journal:  Vasc Health Risk Manag       Date:  2021-09-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.